Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma: Efficacy, Real-World Outcomes, and the Search for Predictive Biomarkers

Immunotherapy has significantly reshaped the management of malignant pleural mesothelioma (MPM), offering new therapeutic opportunities after decades in which platinum–pemetrexed chemotherapy represented the only systemic option. However, clinical benefit remains markedly heterogeneous, with outcome...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Giusi Bondì, Serafina Martella, Dimitrios Stylianakis, Alberto Terminella, Filippo Lococo, Alessia Ciarrocchi, Alfonso Fiorelli, Giacomo Cusumano
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2026-02-01
coleção:	Current Oncology
Assuntos:	malignant pleural mesothelioma immune checkpoint inhibitors biomarkers tumor microenvironment genomic alterations immunotherapy outcomes
Acesso em linha:	https://www.mdpi.com/1718-7729/33/2/93
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!